CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is  a   biotech which has been effective diligently but unsuccessfully to create an one-time therapy, variously called Pro 140, leronlimab, and Vyrologix. In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications. CytoDyn's inventories […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective diligently but unsuccessfully to create an one-time therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn's inventories of leronlimab are building up, whether they'll actually be used is actually an open question.


While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my past few shares. The 1st CytoDyn post of mine, "CytoDyn: What In order to Do When It is Too Good To Be True?", set away the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire interview that I came away with an inadequate impression of the company.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, yet the disappointment hasn't been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc.... has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today's transaction of $3.5 huge number of transfers ownership of this know-how and also associated intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of majority drug substance.... milestone payments after commencement of a level III clinical trial ($1.5 million) and the first new drug program endorsement ($five million), and even royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn's guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple therapies and many indications, it's this individual treatment as well as a "broad pipeline of indications" because it places it. I call some pipelines, "pipedots." In CytoDyn's case it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

Its opening banner on the site of its (below) shows an energetic company with diverse interests albeit focused on leronlimab, several disease types, multiple publications in addition to multiple presentations.

Can it all be smoke cigarettes and mirrors? That's a question I've been asking myself through the really beginning of the interest of mine in this particular organization. Judging by the multiples of a huge number of diverse commentary on listings accessible through Seeking Alpha's CytoDyn Summary page, I'm much from alone in this question.

CytoDyn is a traditional battleground, or maybe some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *